EQS-News: Zur Rose Group: steady growth in a volatile market environment
Retrieved on:
Thursday, January 20, 2022
People, City, Patient, Zur Rose Group, Intention, EBITDA, Plasma protein binding, Pharmacy, Partnership, Federal Ministry of Health (Germany), Growth, Telehealth, Annual, Automation, Obesity, Acquisition, Acceleration, Beauty, OTC, Diabetes, CHF, FMH, B2C, Novo Nordisk, Annual report, Professional services, Pharmaceutical industry, Health insurance, Group, Health, Apote
External revenue rose to CHF 2,034.1 million, equivalent to growth of 15.5 per cent in Group currency terms or 14.8 per cent in local currency terms.
Key Points:
- External revenue rose to CHF 2,034.1 million, equivalent to growth of 15.5 per cent in Group currency terms or 14.8 per cent in local currency terms.
- In Germany the Zur Rose Group posted a considerable rise in external revenue in 2021, up 19.4 per cent in local currency terms.
- Zur Rose continued to expand digital services both for doctors' practices and in the B2C business.
- Like all other stakeholders, the Zur Rose Group expects the binding schedule to be announced as soon as possible.